Loss- and gain-of-function studies demonstrated that expression of NUAK1-targeting shRNA substantially suppressed ESCC cell EMT, migration and invasion in vitro and abrogated the metastatic behavior of ESCC cancer cells in xenograft models, indicating targeting NUAK1 is a promising strategy for the treatment of ESCC patients. The gene discussed is NUAK1; the disease is cancer.